GSK is being nursed back to health
Last September in a review of the pharmaceutical industry I concluded that GlaxoSmithKline (GSK) shares were discounting too much bad news and not enough future potential. Pharmaceutical shares are admittedly a speculative thing, the nature of which regulatory advice constantly warns us. However, all investment involves speculation about the future. If it were any different,…